Cargando…
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
We developed a computational pipeline designed to use RNA sequencing (n = 136) and gene expression profiling (n = 250) data from neuroblastoma tumors to identify cell surface proteins predicted to be highly expressed in MYCN amplified neuroblastomas and with little or no expression in normal human t...
Autores principales: | Sussman, Robyn T., Rokita, Jo Lynne, Huang, Kevin, Raman, Pichai, Rathi, Komal S., Martinez, Daniel, Bosse, Kristopher R., Lane, Maria, Hart, Lori S., Bhatti, Tricia, Pawel, Bruce, Maris, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069022/ https://www.ncbi.nlm.nih.gov/pubmed/32211329 http://dx.doi.org/10.3389/fonc.2020.00302 |
Ejemplares similares
-
Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020) -
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023) -
The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021) -
MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019) -
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)